Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab

2015 ◽  
Vol 75 (23) ◽  
pp. 5084-5092 ◽  
Author(s):  
Yoshinobu Koguchi ◽  
Helena M. Hoen ◽  
Shelly A. Bambina ◽  
Michael D. Rynning ◽  
Richard K. Fuerstenberg ◽  
...  
Keyword(s):  
Overall Survival ◽  
Metastatic Melanoma ◽  
Melanoma Patients

scholarly journals Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

2010 ◽  
Vol 130 (10) ◽  
pp. 2514-2516 ◽  
Author(s):  
Christian Busch ◽  
Jürgen Geisler ◽  
Stian Knappskog ◽  
Johan R. Lillehaug ◽  
Per E. Lønning
Keyword(s):  
Overall Survival ◽  
Metastatic Melanoma ◽  
P53 Pathway ◽  
P16ink4a Expression ◽  
Melanoma Patients

scholarly journals Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

2019 ◽  
Vol 11 ◽  
pp. 175883591984887 ◽  
Author(s):  
Lorena Incorvaia ◽  
Giuseppe Badalamenti ◽  
Gaetana Rinaldi ◽  
Juan Lucio Iovanna ◽  
Daniel Olive ◽  
...  
Keyword(s):  
Immune Response ◽  
Overall Survival ◽  
Survival Rate ◽  
Metastatic Melanoma ◽  
Braf Mutation ◽  
Primary Melanoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Enzyme Linked Immunosorbent Assay ◽  
Melanoma Patients ◽  
Infiltrating Lymphocytes

Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent. Several studies have shown that a greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and higher survival rate. Patients and Methods: We investigated by enzyme-linked immunosorbent assay (ELISA) the correlation between PD-1 levels in plasma and the presence/absence of TILs in 28 patients with metastatic melanoma. Results: Low plasma PD-1 levels were correlated with brisk TILs in primary melanoma, whereas intermediate values correlated with the nonbrisk TILs, and high PD-1 levels with absent TILs. Although the low number of samples did not allow us to obtain a statistically significant correlation between the plasma PD-1 levels and the patients’ overall survival depending on the absence/presence of TILs, the median survival of patients having brisk type TILs was 5 months higher than that of patients with absent and nonbrisk TILs. Conclusions: This work highlights the ability of measuring the plasma PD-1 levels in order to predict the prognosis of patients with untreated metastatic melanoma without a BRAF mutation at the time of diagnosis.

scholarly journals Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Sapoznik Sivan ◽  
Faranesh Suzan ◽  
Ortenberg Rona ◽  
Hamburger Tamar ◽  
Barak Vivian ◽  
...  
Keyword(s):  
Immune Response ◽  
Overall Survival ◽  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Disease Progression ◽  
Skin Test ◽  
Metastatic Disease ◽  
Prognostic Value ◽  
Serum Samples ◽  
Melanoma Patients

The search for melanoma biomarkers is crucial, as the incidence of melanoma continues to rise. We have previously demonstrated that serum CEACAM1 (sCEACAM1) is secreted from melanoma cells and correlates with disease progression in metastatic melanoma patients. Here, we have used a different cohort of melanoma patients with regional or metastatic disease (N=49), treated with autologous vaccination. By monitoring sCEACAM1 in serum samples obtained prior to and after vaccination, we show that sCEACAM1 correlates with disease state, overall survival, and S100B. The trend of change in sCEACAM1 following vaccination (increase/decrease) inversely correlates with overall survival. DTH skin test is used to evaluate patients’ anti-melanoma immune response and to predict response to vaccination. Importantly, sCEACAM1 had a stronger prognostic value than that of DTH, and when sCEACAM1 decreased following treatment, this was the dominant predictor of increased survival. Collectively, our results point out the relevance of sCEACAM1 in monitoring melanoma patients.

Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 10011-10011 ◽  
Author(s):  
Jessica Cecile Hassel ◽  
Hans-Dieter Zucht ◽  
Joanna Mangana ◽  
Reinhard Dummer ◽  
Claudia Pföhler ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adverse Events ◽  
B Cell ◽  
Metastatic Melanoma ◽  
Cell Response ◽  
Statistical Tests ◽  
Cox Regression Analysis ◽  
Melanoma Patients ◽  
Pre Treatment ◽  
B Cell Response

10011 Background: Increasing evidence suggests that the B cell response in cancer patients is an important component of anti-tumour immunity. Autoantibodies targeting tumour and self-antigens may serve as biomarkers of anti-tumour and auto-immunity. As they can be measured in patient' sera, they have great potential as clinical routine biomarkers. The objective of this study was to explore if autoantibodies are associated with survival and immune related adverse events (irAE) in patients with metastatic melanoma under checkpoint inhitibor (CPI) therapy. Methods: Pre-treatment serum samples from 333 metastatic melanoma patients receiving CPI therapy at 5 European centers were retrospectively used to identify autoantibody signatures for survival and irAE. We designed a cancer immunotherapy antigen array comprising 832 autoimmune and tumour antigens as well as immune and cancer pathway proteins. Statistical tests were separately performed for patients treated with anti-CTLA4 (alone or in combination) and with anti-PD1 antibody monotherapy. Cox-regression analysis and univariate statistical tests were applied for biomarker discovery. Progression free and overall survival was measured from treatment initiation to tumor progression or death date. irAE were recorded including onset date and grade (CTC-AE). Results: For each therapy group we identified a set of autoantibody reactivities in untreated melanoma patients that were associated with the development of irAEs and/or survival. The identified autoantibodies target a diverse set of antigens comprising neoantigens (p53), cancer testis antigens (MAGEB4), paraneoplastic antigens (gephyrin), autoantigens (ribosomal proteins, Nor-90) and FGFR1. Autoantigens that correlated with irAE and survival were e.g. anti-MAGEB4 and anti-FGFR1. Elevated anti-MAGEB4 pre-treatment levels were associated with longer overall survival (p = 0.002, HR = 0.77) and the development of irAEs (p = 0.002, HR = 1.27) in ipilimumab +/- nivolumab treated patients. Higher pre-treatment anti-FGFR1 antibodies were associated with shorter survival (p = 0.008, HR = 1.27) and a lower a lower frequency of irAEs (p = 0.04, HR = 0.69) in these patients. Conclusions: We identified autoantibody targets suggesting a diverse B cell response to antigens expressed in tumours and those associated with autoimmunity. Depending on the specific antigen, the immune response towards those antigens may be associated with anti-tumour or pro-tumour responses.

scholarly journals Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

2015 ◽  
Vol 3 (S2) ◽  
Author(s):  
Yoshinobu Koguchi ◽  
Helena Hoen ◽  
Shelly Bambina ◽  
Michael Rynning ◽  
Richard Fuerstenberg ◽  
...  
Keyword(s):  
Overall Survival ◽  
Metastatic Melanoma ◽  
Melanoma Patients
Sign in / Sign up

Export Citation Format

Share Document